|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-12-2
|
|
pubmed:abstractText |
S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. This article presents a population pharmacokinetic analysis of these four compounds in Western cancer patients. The second objective was to compare the pharmacokinetics of S-1 in Western and Japanese patients.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-10447576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-10473078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-10499595,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-10894878,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-10912578,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-11014408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-11106261,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-2060083,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-2348382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-2656050,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-3943107,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-7586945,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-7689420,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-9140762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-9440757,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14650374-9795879
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1567-567X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
257-83
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:14650374-Administration, Oral,
pubmed-meshheading:14650374-Adult,
pubmed-meshheading:14650374-Aged,
pubmed-meshheading:14650374-Antimetabolites, Antineoplastic,
pubmed-meshheading:14650374-Asian Continental Ancestry Group,
pubmed-meshheading:14650374-Chi-Square Distribution,
pubmed-meshheading:14650374-Clinical Trials as Topic,
pubmed-meshheading:14650374-Drug Combinations,
pubmed-meshheading:14650374-Europe,
pubmed-meshheading:14650374-Female,
pubmed-meshheading:14650374-Humans,
pubmed-meshheading:14650374-Male,
pubmed-meshheading:14650374-Middle Aged,
pubmed-meshheading:14650374-Models, Biological,
pubmed-meshheading:14650374-Oxonic Acid,
pubmed-meshheading:14650374-Pyridines,
pubmed-meshheading:14650374-Statistics, Nonparametric,
pubmed-meshheading:14650374-Tegafur,
pubmed-meshheading:14650374-United States,
pubmed-meshheading:14650374-Western World
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
|
|
pubmed:affiliation |
Department of Pharmacy, Keio University Hospital, Tokyo 160-8582, Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
